Contingency Medical Countermeasures for Mass Nerve-Agent Exposure: Use of Pharmaceutical Alternatives to Community Stockpiled Antidotes

Michael D. Schwartz, Mark E. Sutter, Derek Eisnor, Mark A. Kirk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Having sufficient medical countermeasures (MCMs) available for the treatment of acetylcholinesterase-inhibiting nerve agent poisoned patients following a mass chemical exposure is a challenge for communities. After stockpiles containing auto-injectors are exhausted, communities need to be aware of alternative pharmaceutical options. The Department of Homeland Security Chemical Defense Program convened a federal interagency working group consisting of first responders, clinicians, and experts from the fields of medical toxicology, pharmacology, and emergency management. A literature review of pharmaceutical alternatives for treating nerve agent toxicity was performed. Pharmaceuticals that met the federal Public Health Emergency Medical Countermeasures Enterprise Product Specific Requirements were prioritized. Food and Drug Administration approval for one indication, market availability, and alignment to government procurement strategy were considered. This article summarizes the literature on comparative pharmacokinetics and efficacy against nerve agents (where available) of Food and Drug Administration approved drugs with muscarinic acetylcholine receptor antagonist and gamma-aminobutyric acid receptor agonist effects. This work is intended to serve as a resource of pharmaceutical options that may be available to communities (ie, emergency managers, planners, clinicians, and poison centers) when faced with a mass human exposure to a nerve agent and inadequate supplies of MCMs. (Disaster Med Public Health Preparedness. 2018;page 1 of 8)

Original languageEnglish (US)
JournalDisaster Medicine and Public Health Preparedness
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Antidotes
Emergencies
Pharmaceutical Preparations
United States Food and Drug Administration
Public Health
GABA Agonists
Drug Approval
GABA Receptors
Poisons
Cholinergic Antagonists
Disasters
Muscarinic Receptors
Acetylcholinesterase
Toxicology
Pharmacokinetics
Nerve Agents
Pharmacology

Keywords

  • medical countermeasures
  • nerve agents
  • pharmaceutical options

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Contingency Medical Countermeasures for Mass Nerve-Agent Exposure : Use of Pharmaceutical Alternatives to Community Stockpiled Antidotes. / Schwartz, Michael D.; Sutter, Mark E.; Eisnor, Derek; Kirk, Mark A.

In: Disaster Medicine and Public Health Preparedness, 01.01.2018.

Research output: Contribution to journalArticle

@article{1017aef5e99a4aab9e87343f6bfaf00e,
title = "Contingency Medical Countermeasures for Mass Nerve-Agent Exposure: Use of Pharmaceutical Alternatives to Community Stockpiled Antidotes",
abstract = "Having sufficient medical countermeasures (MCMs) available for the treatment of acetylcholinesterase-inhibiting nerve agent poisoned patients following a mass chemical exposure is a challenge for communities. After stockpiles containing auto-injectors are exhausted, communities need to be aware of alternative pharmaceutical options. The Department of Homeland Security Chemical Defense Program convened a federal interagency working group consisting of first responders, clinicians, and experts from the fields of medical toxicology, pharmacology, and emergency management. A literature review of pharmaceutical alternatives for treating nerve agent toxicity was performed. Pharmaceuticals that met the federal Public Health Emergency Medical Countermeasures Enterprise Product Specific Requirements were prioritized. Food and Drug Administration approval for one indication, market availability, and alignment to government procurement strategy were considered. This article summarizes the literature on comparative pharmacokinetics and efficacy against nerve agents (where available) of Food and Drug Administration approved drugs with muscarinic acetylcholine receptor antagonist and gamma-aminobutyric acid receptor agonist effects. This work is intended to serve as a resource of pharmaceutical options that may be available to communities (ie, emergency managers, planners, clinicians, and poison centers) when faced with a mass human exposure to a nerve agent and inadequate supplies of MCMs. (Disaster Med Public Health Preparedness. 2018;page 1 of 8)",
keywords = "medical countermeasures, nerve agents, pharmaceutical options",
author = "Schwartz, {Michael D.} and Sutter, {Mark E.} and Derek Eisnor and Kirk, {Mark A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1017/dmp.2018.99",
language = "English (US)",
journal = "Disaster Medicine and Public Health Preparedness",
issn = "1935-7893",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Contingency Medical Countermeasures for Mass Nerve-Agent Exposure

T2 - Use of Pharmaceutical Alternatives to Community Stockpiled Antidotes

AU - Schwartz, Michael D.

AU - Sutter, Mark E.

AU - Eisnor, Derek

AU - Kirk, Mark A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Having sufficient medical countermeasures (MCMs) available for the treatment of acetylcholinesterase-inhibiting nerve agent poisoned patients following a mass chemical exposure is a challenge for communities. After stockpiles containing auto-injectors are exhausted, communities need to be aware of alternative pharmaceutical options. The Department of Homeland Security Chemical Defense Program convened a federal interagency working group consisting of first responders, clinicians, and experts from the fields of medical toxicology, pharmacology, and emergency management. A literature review of pharmaceutical alternatives for treating nerve agent toxicity was performed. Pharmaceuticals that met the federal Public Health Emergency Medical Countermeasures Enterprise Product Specific Requirements were prioritized. Food and Drug Administration approval for one indication, market availability, and alignment to government procurement strategy were considered. This article summarizes the literature on comparative pharmacokinetics and efficacy against nerve agents (where available) of Food and Drug Administration approved drugs with muscarinic acetylcholine receptor antagonist and gamma-aminobutyric acid receptor agonist effects. This work is intended to serve as a resource of pharmaceutical options that may be available to communities (ie, emergency managers, planners, clinicians, and poison centers) when faced with a mass human exposure to a nerve agent and inadequate supplies of MCMs. (Disaster Med Public Health Preparedness. 2018;page 1 of 8)

AB - Having sufficient medical countermeasures (MCMs) available for the treatment of acetylcholinesterase-inhibiting nerve agent poisoned patients following a mass chemical exposure is a challenge for communities. After stockpiles containing auto-injectors are exhausted, communities need to be aware of alternative pharmaceutical options. The Department of Homeland Security Chemical Defense Program convened a federal interagency working group consisting of first responders, clinicians, and experts from the fields of medical toxicology, pharmacology, and emergency management. A literature review of pharmaceutical alternatives for treating nerve agent toxicity was performed. Pharmaceuticals that met the federal Public Health Emergency Medical Countermeasures Enterprise Product Specific Requirements were prioritized. Food and Drug Administration approval for one indication, market availability, and alignment to government procurement strategy were considered. This article summarizes the literature on comparative pharmacokinetics and efficacy against nerve agents (where available) of Food and Drug Administration approved drugs with muscarinic acetylcholine receptor antagonist and gamma-aminobutyric acid receptor agonist effects. This work is intended to serve as a resource of pharmaceutical options that may be available to communities (ie, emergency managers, planners, clinicians, and poison centers) when faced with a mass human exposure to a nerve agent and inadequate supplies of MCMs. (Disaster Med Public Health Preparedness. 2018;page 1 of 8)

KW - medical countermeasures

KW - nerve agents

KW - pharmaceutical options

UR - http://www.scopus.com/inward/record.url?scp=85055318045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055318045&partnerID=8YFLogxK

U2 - 10.1017/dmp.2018.99

DO - 10.1017/dmp.2018.99

M3 - Article

AN - SCOPUS:85055318045

JO - Disaster Medicine and Public Health Preparedness

JF - Disaster Medicine and Public Health Preparedness

SN - 1935-7893

ER -